Expert Interview
Discussing Fulcrum Therapeutics' Phase 1b PIONEER Trial of Pociredir and Beam Therapeutics' Phase 1/2 clinical trial for BEAM-101 in Sickle Cell Disease.
Ticker(s): FULC, BEAMInstitution: Columbia University
- Pediatric Hematology-Oncology Physician at Columbia University Irving Cancer Center
- Manages over 50 patients with for sickle cell disease with VOCs
- Special research and clinical interest in reducing the toxicity of current SCD treatments
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
